AAAAAA

   
Results: 1-25 | 26-26
Results: 1-25/26
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoxome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome
Authors: Dabaja, BS O'Brien, SM Kantarjian, HM Cortes, JE Thomas, DA Albitar, M Schlette, ES Faderl, S Sarris, A Keating, MJ Giles, FJ
Citation: Bs. Dabaja et al., Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoxome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome, LEUK LYMPH, 42(3), 2001, pp. 329-337
The clinical significance of caspase regulation in acute leukemia
Authors: Faderl, S Estrov, Z
Citation: S. Faderl et Z. Estrov, The clinical significance of caspase regulation in acute leukemia, LEUK LYMPH, 40(5-6), 2001, pp. 471-481
Loss of heterozygosity on chromosome 5 in adults with acute lymphoblastic leukemia
Authors: Faderl, S Gidel, C Kantarjian, HM Manshouri, T Keating, M Albitar, M
Citation: S. Faderl et al., Loss of heterozygosity on chromosome 5 in adults with acute lymphoblastic leukemia, LEUK RES, 25(1), 2001, pp. 39-43
High-dose chemotherapy in high-risk myelodysplastic syndrome - Covariate-adjusted comparison of five regimens
Authors: Beran, M Shen, Y Kantarjian, H O'Brien, S Koller, CA Giles, FJ Cortes, J Thomas, DA Faderl, S Despa, S Estey, EH
Citation: M. Beran et al., High-dose chemotherapy in high-risk myelodysplastic syndrome - Covariate-adjusted comparison of five regimens, CANCER, 92(8), 2001, pp. 1999-2015
Expression of apoptosis proteins in chronic myelogenous leukemia - Associations and significance
Authors: Ravandi, F Kantarjian, HM Talpaz, M O'Brien, S Faderl, S Giles, FJ Thomas, D Cortes, J Andreeff, M Estrov, Z Rios, MB Albitar, M
Citation: F. Ravandi et al., Expression of apoptosis proteins in chronic myelogenous leukemia - Associations and significance, CANCER, 91(11), 2001, pp. 1964-1972
Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia
Authors: Talpaz, M O'Brien, S Rose, E Gupta, S Shan, JQ Cortes, J Giles, FJ Faderl, S Kantarjian, HM
Citation: M. Talpaz et al., Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia, BLOOD, 98(6), 2001, pp. 1708-1713
Hematopoietic growth factors and cytokines
Authors: Faderl, S Estrov, Z
Citation: S. Faderl et Z. Estrov, Hematopoietic growth factors and cytokines, J CLIN LIG, 23(3), 2000, pp. 169-180
Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia
Authors: Faderl, S Kantarjian, HM Thomas, DA Cortes, J Giles, F Pierce, S Albitar, M Estrov, Z
Citation: S. Faderl et al., Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia, LEUK LYMPH, 36(3-4), 2000, pp. 263-273
Clinical significance of minimal residual disease in leukemia (Review)
Authors: Faderl, S Kantarjian, HM Talpaz, M Estrov, Z
Citation: S. Faderl et al., Clinical significance of minimal residual disease in leukemia (Review), INT J ONCOL, 17(6), 2000, pp. 1277-1287
Insights into the biologic and molecular abnormalities in adult acute lymphocytic leukemia
Authors: Faderl, S Albitar, M
Citation: S. Faderl et M. Albitar, Insights into the biologic and molecular abnormalities in adult acute lymphocytic leukemia, HEMAT ONCOL, 14(6), 2000, pp. 1267
New treatment approaches for chronic myelogenous leukemia
Authors: Faderl, S Kantarjian, HM Talpaz, M O'Brien, S
Citation: S. Faderl et al., New treatment approaches for chronic myelogenous leukemia, SEMIN ONCOL, 27(5), 2000, pp. 578-586
The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia
Authors: Faderl, S Kantarjian, HM Estey, E Manshouri, T Chan, CY Elsaied, AR Kornblau, SM Cortes, J Thomas, DA Pierce, S Keating, MJ Estrov, Z Albitar, M
Citation: S. Faderl et al., The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia, CANCER, 89(9), 2000, pp. 1976-1982
Avascular necrosis of the femoral head in chronic myeloid leukemia patients treated with interferon-alpha - A synergistic correlation?
Authors: Kozuch, P Talpaz, M Faderl, S O'Brien, S Freireich, EJ Kantarjian, H
Citation: P. Kozuch et al., Avascular necrosis of the femoral head in chronic myeloid leukemia patients treated with interferon-alpha - A synergistic correlation?, CANCER, 89(7), 2000, pp. 1482-1489
The incidence of chromosome 9p21 abnormalities and deletions of tumor suppressor genes p15(INK4b)/p16(INK4a)/p14(ARF) in patients with acute lymphoblastic leukemia
Authors: Faderl, S Estrov, Z Kantarjian, HM Thomas, D Cortes, J Manshouri, T Chan, CC Hays, KJ Pierce, S Albitar, M
Citation: S. Faderl et al., The incidence of chromosome 9p21 abnormalities and deletions of tumor suppressor genes p15(INK4b)/p16(INK4a)/p14(ARF) in patients with acute lymphoblastic leukemia, CYTOK CELL, 5(3), 1999, pp. 159-163
The prognostic significance of p16(INK4a)/p14(ARF) and p15(INK4b) deletions in adult acute lymphoblastic leukemia
Authors: Faderl, S Kantarjian, HM Manshouri, T Chan, CY Pierce, S Hays, KJ Cortes, J Thomas, D Estrov, Z Albitar, M
Citation: S. Faderl et al., The prognostic significance of p16(INK4a)/p14(ARF) and p15(INK4b) deletions in adult acute lymphoblastic leukemia, CLIN CANC R, 5(7), 1999, pp. 1855-1861
Caspase 2 and caspase 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemia
Authors: Faderl, S Thall, PF Kantarjian, HM Talpaz, M Harris, D Van, Q Beran, M Kornblau, SM Pierce, S Estrov, Z
Citation: S. Faderl et al., Caspase 2 and caspase 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemia, CLIN CANC R, 5(12), 1999, pp. 4041-4047
Chronic myelogenous leukemia: Update on biology and treatment
Authors: Faderl, S Kantarjian, HM Talpaz, M
Citation: S. Faderl et al., Chronic myelogenous leukemia: Update on biology and treatment, ONCOLOGY-NY, 13(2), 1999, pp. 169-180
Deletions and losses in chromosomes 5 or 7 in adult acute lymphocytic leukemia: incidence, associations and implications
Authors: Dabaja, BS Faderl, S Thomas, D Cortes, J O'Brien, S Nasr, F Pierce, S Hayes, K Glassman, A Keating, M Kantarjian, HM
Citation: Bs. Dabaja et al., Deletions and losses in chromosomes 5 or 7 in adult acute lymphocytic leukemia: incidence, associations and implications, LEUKEMIA, 13(6), 1999, pp. 869-872
Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia
Authors: Thomas, DA Cortes, J O'Brien, S Pierce, S Faderl, S Albitar, M Hagemeister, FB Cabanillas, FF Murphy, S Keating, MJ Kantarjian, H
Citation: Da. Thomas et al., Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia, J CL ONCOL, 17(8), 1999, pp. 2461-2470
Mechanisms of disease - The biology of chronic myeloid leukemia
Authors: Faderl, S Talpaz, M Estrov, Z O'Brien, S Kurzrock, R Kantarjian, HM
Citation: S. Faderl et al., Mechanisms of disease - The biology of chronic myeloid leukemia, N ENG J MED, 341(3), 1999, pp. 164-172
Detection of residual disease in childhood acute lymphoblastic leukemia
Authors: Faderl, S Estrov, Z
Citation: S. Faderl et Z. Estrov, Detection of residual disease in childhood acute lymphoblastic leukemia, N ENG J MED, 340(2), 1999, pp. 152-153
Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction and clinical decision making - Response
Authors: Faderl, S Talpaz, M Kantarjian, HM Estrov, Z
Citation: S. Faderl et al., Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction and clinical decision making - Response, BLOOD, 94(4), 1999, pp. 1487-1488
Polymerase chain reaction analyses should be used as a basis for clinical decision making in patients with chronic myelogenous leukemia - Response
Authors: Faderl, S Talpaz, M Kantarjian, HM Estrov, Z
Citation: S. Faderl et al., Polymerase chain reaction analyses should be used as a basis for clinical decision making in patients with chronic myelogenous leukemia - Response, BLOOD, 94(10), 1999, pp. 3610-3611
Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making?
Authors: Faderl, S Talpaz, M Kantarjian, HM Estrov, Z
Citation: S. Faderl et al., Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making?, BLOOD, 93(9), 1999, pp. 2755-2759
Minimal residual disease in hematologic disorders
Authors: Faderl, S Kurzrock, R Estrov, Z
Citation: S. Faderl et al., Minimal residual disease in hematologic disorders, ARCH PATH L, 123(11), 1999, pp. 1030-1034
Risultati: 1-25 | 26-26